InMed Pharmaceuticals (INM) AI Stock Analysis

• Market Cap: $2.50M
• Dividend Yield: N/A
• Average Volume (3M): 30.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: -11.94%
• EPS Growth: 56.72%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -14.28
• Shares Outstanding: 1,207,186
• 10 Day Avg. Volume: 13,918
• 30 Day Avg. Volume: 30,940
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.38
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall stock score reflects significant financial struggles, with persistent losses and negative cash flows posing long-term risks. The technical analysis indicates a bearish trend with potential for minor short-term recovery. Despite the promising corporate event regarding CBN's potential, valuation challenges with a negative P/E ratio and no dividend yield limit immediate attractiveness.

InMed Pharmaceuticals Business Overview & Revenue Model

Company Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

How the Company Makes Money

InMed Pharmaceuticals generates revenue through various channels primarily centered around its cannabinoid-based drug development and manufacturing capabilities. The company earns income by developing proprietary cannabinoid therapeutics aimed at treating specific medical conditions, which may involve licensing agreements, milestone payments, and potential royalties from pharmaceutical partners. In addition, InMed produces and supplies rare cannabinoids for commercial use, offering these compounds to other pharmaceutical companies and research institutions. The company's partnerships and collaborations with other biotech firms and research organizations also contribute to its revenue streams, providing financial support and shared resources to advance its development programs.

InMed Pharmaceuticals Financial Statement Overview

Summary

InMed Pharmaceuticals faces significant financial challenges, with persistent operational losses impacting profitability and cash flow. Despite a relatively strong balance sheet with low leverage, the sustained negative earnings and cash flow trends may threaten long-term viability unless growth in revenue and operational efficiency can be achieved.

Income Statement

InMed Pharmaceuticals shows a volatile income statement with consistent losses. The company reported a significant negative gross profit margin and net profit margin in the TTM period, indicating high expenses relative to low revenues. Revenue growth is present but from a very low base, and both EBIT and EBITDA margins are substantially negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio, indicating good financial stability. However, return on equity is negative due to the persistent net losses. The equity ratio is strong, showing reliance on equity financing, but ongoing losses pose a risk to sustainability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating that the company is not generating positive cash from its core operations. The operating cash flow to net income ratio is poor, reflecting inefficiency in converting net losses into positive cash flows. The company relies on financing activities to support its operations.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.12B	4.60M	4.14M	1.09M	0.00	0.00
	Gross Profit
-6.53B	1.10M	1.40M	543.55K	-197.03K	-183.09K
	EBIT
-2.15B	0.00	-8.18B	-13.70M	-9.92M	―
	EBITDA
-2.11B	-7.06M	-10.83M	-17.26M	-9.80M	―
	Net Income Common Stockholders
-4.26B	-7.68M	-7.95M	-18.60M	-10.20M	-8.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
0.00	6.61M	8.91M	6.22M	7.41M	5.84M
	Total Assets
204.45K	11.82M	14.11M	12.79M	9.78M	7.50M
	Total Debt
211.07K	962.66K	391.71K	793.77K	269.77K	316.28K
	Net Debt
211.07K	-5.61M	-8.52M	-5.38M	-7.09M	-5.48M
	Total Liabilities
1.47M	2.62M	2.02M	3.71M	2.40M	1.92M
	Stockholders Equity
―	9.21M	12.09M	9.08M	7.38M	5.58M
Cash Flow		Free Cash Flow
-5.36M	-7.00M	-7.45M	-15.62M	-9.79M	―
	Operating Cash Flow
-7.32M	-6.99M	-7.28M	-15.58M	-9.79M	―
	Investing Cash Flow
0.00	-9.29K	-661.80K	-673.00K	-1.73K	3.62M
	Financing Cash Flow
1.21M	4.65M	10.68M	15.07M	10.85M	―

InMed Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INM, the sentiment is Negative. The current price of 2.08 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 3.04, and below the 200-day MA of 4.47, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 26.72 is Positive, neither overbought nor oversold. The STOCH value of 5.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INM.

InMed Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCNI	52 Neutral	$2.30M	9.21	99.42%	―	―	―
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
GRI	42 Neutral	$1.68M	―	-382.57%	―	―	98.55%
INM	40 Underperform	$2.50M	―	-83.50%	―	-11.94%	56.72%
GLMD	40 Underperform	$2.39M	―	-37.32%	―	―	73.90%
SHPH	31 Underperform	$2.43M	―	-383.84%	―	―	-7.18%
REVB	28 Underperform	$2.38M	―	-264.85%	―	―	-115.81%

InMed Pharmaceuticals Corporate Events

InMed Pharmaceuticals Board Reshuffle After Director Resignation

InMed Pharmaceuticals Inc. announced that Ms. Janet Grove’s resignation from the Board of Directors was accepted on February 10, 2025, following the withholding of her election by the company’s shareholders at the 2024 Annual General Meeting on December 18, 2024. The Board will seek an independent director to replace Ms. Grove, while the Board Chair will temporarily assume her role as Chair of the Nominating & Governance Committee.

InMed Pharmaceuticals Reports Q2 2025 Financial Results

On February 12, 2025, InMed Pharmaceuticals reported its financial results for the second quarter of fiscal 2025, which ended on December 31, 2024. The company highlighted progress in its pharmaceutical pipeline, notably with INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration. Despite a net loss of $2.6 million for the quarter, InMed’s BayMedica business unit achieved a 189% improvement in net income compared to the previous year, despite a 10% revenue decrease. The company plans to continue focusing on advancing its drug candidates while managing expenses.